Home
Ultragenyx

Ultragenyx Market Share Analysis for March 2026

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need.

Health > Biotechnology and Pharmaceuticals

Domainultragenyx.com

Year Founded2010

Employees1001 - 5000

Annual Revenue$200M - $500M

Ultragenyx

Ultragenyx (including company regionals)

ultragenyx.com

See more website traffic and engagement information

Ultragenyx Revenue up to March 2026 is 200M - 500M

revenue generated by Ultragenyx top domains

Ultragenyx top domains revenue over 3 years

Revenue for Ultragenyx top domains

ultragenyx.com200M - 500M

See more with Sales Intelligence

Total visits to Ultragenyx's top domains

Understand Ultragenyx market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

ultragenyx.com45.6K

See more with Sales Intelligence

Avg. visit duration in Ultragenyx's top domains

Analyze Ultragenyx engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

ultragenyx.com00:01:10

See more with Sales Intelligence

Avg. pageviews on Ultragenyx's top domains

See how Ultragenyx keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

ultragenyx.com3.44

See more with Sales Intelligence

Ultragenyx top competitors by domain

Top similar sites in March 2026, ranked by their affinity

vazyme.comCompany NameVazymeEmployees1001 - 5000HQChina, NanjingAnnual revenue$50M - $75MTotal visits55.6KScience and Education > Biology

Top technologies used by Ultragenyx

These are the website technologies, by industry, used by Ultragenyx top domains

Payment & Currencies (11)

Cart Functionality

eCommerce (5)

OpenCart

Marketing (4)

Google Marketing Platform

Widget (4)

Twemoji

More Technologies

14

See all

News & Signals from Ultragenyx

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsUltragenyx Pharmaceutical Inc. has issues with securities fraud lawsuit.RARE deadline: RARE investors with losses in excess of $100K have opportunity to lead Ultragenyx Pharmaceutical Inc. securities fraud lawsuit.

NewsUltragenyx Pharmaceutical Inc. is developing UX111.Ultragenyx announced that the FDA accepted for review its resubmitted Biologics License Application for UX111, an AAV9 gene therapy for Sanfilippo syndrome Type A, under a potential accelerated approval pathway, moving the program into a formal regulatory review phase.

NewsUltragenyx Pharmaceutical Inc. is developing Investigational New Drug application for UX016 on Mar 30th '26.NOVATO, Calif., March 30, 2026 (GLOBE NEWSWIRE) - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UX016, an investigational small molecule prodrug of sialic acid (SA) being evaluated as a substrate replacement therapy for GNE myopathy (GNEM).